EGFR and cancer: Consistent with previously published studies [19,20,21], we found pathways in cancer were significantly affected in PanNETs and liver metastases, and that EGFR tyrosine kinase inhibitor resistance and transcriptional misregulation in cancer were unique to liver metastases via KEGG pathway analysis; simultaneously, GO Biological Processes analysis underlined those signaling pathways tightly related to tyrosine phosphorylation, DNA repair, and cell cycle regulation, especially in liver metastases (Table 3, Supplementary Table S1).